Alnylam Pharmaceuticals Stock Debt To Equity

ALNY Stock

USD 244.89 1.91 0.77%

Alnylam Pharmaceuticals fundamentals help investors to digest information that contributes to Alnylam Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Alnylam Stock. The fundamental analysis module provides a way to measure Alnylam Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alnylam Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	Debt To Equity	(10.87)	(10.32)

Debt To Equity is likely to rise to -10.32 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Alnylam Pharmaceuticals Company Debt To Equity Analysis

Alnylam Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current Alnylam Pharmaceuticals Debt To Equity

5.63 %

Most of Alnylam Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alnylam Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Alnylam Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Alnylam Pharmaceuticals is extremely important. It helps to project a fair market value of Alnylam Stock properly, considering its historical fundamentals such as Debt To Equity. Since Alnylam Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alnylam Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alnylam Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Short Term Debt	Intangible Assets	Net Receivables	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.1	0.6	-0.97	0.75	0.96	0.91	0.99	0.96	0.43	0.85	0.46	0.82	0.87	0.83	-0.13	0.98	-0.65	-0.58	0.77	-0.86	-0.89	0.47	0.92
Total Stockholder Equity	-0.1		-0.71	0.26	0.05	-0.11	-0.49	-0.08	-0.19	0.27	-0.56	0.1	-0.38	-0.52	0.28	1.0	-0.08	-0.46	0.12	-0.65	-0.12	0.38	-0.58	-0.45
Net Debt	0.6	-0.71		-0.71	0.27	0.67	0.81	0.58	0.7	0.05	0.83	0.27	0.86	0.85	0.21	-0.72	0.63	-0.03	-0.48	0.86	-0.46	-0.74	0.51	0.79
Retained Earnings	-0.97	0.26	-0.71		-0.77	-0.95	-0.96	-0.96	-0.98	-0.33	-0.92	-0.49	-0.88	-0.92	-0.78	0.29	-0.98	0.55	0.63	-0.85	0.85	0.96	-0.48	-0.96
Accounts Payable	0.75	0.05	0.27	-0.77		0.72	0.63	0.72	0.75	0.27	0.62	0.41	0.46	0.54	0.85	0.02	0.75	-0.6	-0.42	0.48	-0.72	-0.73	0.23	0.62
Short Term Investments	0.96	-0.11	0.67	-0.95	0.72		0.89	0.94	0.96	0.45	0.82	0.47	0.82	0.85	0.78	-0.14	0.96	-0.55	-0.71	0.73	-0.91	-0.87	0.44	0.9
Total Liab	0.91	-0.49	0.81	-0.96	0.63	0.89		0.9	0.91	0.27	0.97	0.36	0.87	0.97	0.61	-0.52	0.89	-0.38	-0.56	0.94	-0.7	-0.93	0.64	0.99
Total Current Assets	0.99	-0.08	0.58	-0.96	0.72	0.94	0.9		0.93	0.35	0.86	0.42	0.81	0.88	0.82	-0.12	0.97	-0.68	-0.54	0.79	-0.83	-0.86	0.51	0.9
Property Plant Equipment	0.96	-0.19	0.7	-0.98	0.75	0.96	0.91	0.93		0.42	0.85	0.58	0.9	0.87	0.77	-0.21	0.98	-0.52	-0.71	0.78	-0.9	-0.95	0.35	0.93
Current Deferred Revenue	0.43	0.27	0.05	-0.33	0.27	0.45	0.27	0.35	0.42		0.1	0.61	0.22	0.13	0.46	0.26	0.38	-0.25	-0.34	0.02	-0.41	-0.22	0.07	0.36
Long Term Debt	0.85	-0.56	0.83	-0.92	0.62	0.82	0.97	0.86	0.85	0.1		0.35	0.85	0.98	0.55	-0.58	0.84	-0.35	-0.48	0.98	-0.63	-0.9	0.68	0.95
Short Term Debt	0.46	0.1	0.27	-0.49	0.41	0.47	0.36	0.42	0.58	0.61	0.35		0.49	0.31	0.45	0.09	0.53	-0.31	-0.5	0.28	-0.57	-0.46	-0.09	0.48
Intangible Assets	0.82	-0.38	0.86	-0.88	0.46	0.82	0.87	0.81	0.9	0.22	0.85	0.49		0.9	0.53	-0.4	0.87	-0.37	-0.6	0.84	-0.73	-0.89	0.33	0.88
Net Receivables	0.87	-0.52	0.85	-0.92	0.54	0.85	0.97	0.88	0.87	0.13	0.98	0.31	0.9		0.55	-0.54	0.87	-0.39	-0.5	0.97	-0.65	-0.89	0.66	0.95
Common Stock	0.83	0.28	0.21	-0.78	0.85	0.78	0.61	0.82	0.77	0.46	0.55	0.45	0.53	0.55		0.24	0.82	-0.82	-0.44	0.43	-0.79	-0.7	0.21	0.62
Net Tangible Assets	-0.13	1.0	-0.72	0.29	0.02	-0.14	-0.52	-0.12	-0.21	0.26	-0.58	0.09	-0.4	-0.54	0.24		-0.11	-0.41	0.13	-0.68	-0.1	0.41	-0.59	-0.48
Capital Surpluse	0.98	-0.08	0.63	-0.98	0.75	0.96	0.89	0.97	0.98	0.38	0.84	0.53	0.87	0.87	0.82	-0.11		-0.64	-0.63	0.77	-0.9	-0.91	0.36	0.9
Deferred Long Term Liab	-0.65	-0.46	-0.03	0.55	-0.6	-0.55	-0.38	-0.68	-0.52	-0.25	-0.35	-0.31	-0.37	-0.39	-0.82	-0.41	-0.64		0.1	-0.26	0.56	0.42	-0.07	-0.37
Long Term Investments	-0.58	0.12	-0.48	0.63	-0.42	-0.71	-0.56	-0.54	-0.71	-0.34	-0.48	-0.5	-0.6	-0.5	-0.44	0.13	-0.63	0.1		-0.42	0.84	0.67	-0.07	-0.59
Long Term Debt Total	0.77	-0.65	0.86	-0.85	0.48	0.73	0.94	0.79	0.78	0.02	0.98	0.28	0.84	0.97	0.43	-0.68	0.77	-0.26	-0.42		-0.52	-0.85	0.71	0.92
Short Long Term Debt	-0.86	-0.12	-0.46	0.85	-0.72	-0.91	-0.7	-0.83	-0.9	-0.41	-0.63	-0.57	-0.73	-0.65	-0.79	-0.1	-0.9	0.56	0.84	-0.52		0.8	-0.12	-0.73
Net Invested Capital	-0.89	0.38	-0.74	0.96	-0.73	-0.87	-0.93	-0.86	-0.95	-0.22	-0.9	-0.46	-0.89	-0.89	-0.7	0.41	-0.91	0.42	0.67	-0.85	0.8		-0.39	-0.93
Net Working Capital	0.47	-0.58	0.51	-0.48	0.23	0.44	0.64	0.51	0.35	0.07	0.68	-0.09	0.33	0.66	0.21	-0.59	0.36	-0.07	-0.07	0.71	-0.12	-0.39		0.6
Capital Stock	0.92	-0.45	0.79	-0.96	0.62	0.9	0.99	0.9	0.93	0.36	0.95	0.48	0.88	0.95	0.62	-0.48	0.9	-0.37	-0.59	0.92	-0.73	-0.93	0.6

Click cells to compare fundamentals

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Competition

Predict Alnylam Pharmaceuticals

Debt To Equity Over Time

Alnylam Total Stockholder Equity

Total Stockholder Equity

(209.61 Million)

Alnylam Pharmaceuticals reported Total Stockholder Equity of (220.64 Million) in 2023

According to the company disclosure, Alnylam Pharmaceuticals has a Debt To Equity of 5.629%. This is 89.49% lower than that of the Biotechnology sector and 70.92% lower than that of the Health Care industry. The debt to equity for all United States stocks is 88.44% higher than that of the company.

Alnylam Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alnylam Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alnylam Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alnylam Pharmaceuticals by comparing valuation metrics of similar companies.

Alnylam Pharmaceuticals is currently under evaluation in debt to equity category among its peers.

Alnylam Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Alnylam Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Alnylam Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Alnylam Fundamentals

	Return On Equity	-15.01
	Return On Asset	-0.0292
	Profit Margin	(0.16) %
	Operating Margin	(0.15) %
	Current Valuation	30.11 B
	Shares Outstanding	128.98 M
	Shares Owned By Insiders	0.42 %
	Shares Owned By Institutions	98.05 %
	Number Of Shares Shorted	3.7 M
	Price To Earning	(22.92) X
	Price To Book	976.27 X
	Price To Sales	15.08 X
	Revenue	1.83 B
	Gross Profit	868.6 M
	EBITDA	(258.24 M)
	Net Income	(440.24 M)
	Cash And Equivalents	2.27 B
	Cash Per Share	18.41 X
	Total Debt	2.68 B
	Debt To Equity	5.63 %
	Current Ratio	3.48 X
	Book Value Per Share	0.25 X
	Cash Flow From Operations	104.16 M
	Short Ratio	4.60 X
	Earnings Per Share	(2.62) X
	Price To Earnings To Growth	(0.49) X
	Target Price	301.21
	Number Of Employees	2.1 K
	Beta	0.39
	Market Capitalization	31.59 B
	Total Asset	3.83 B
	Retained Earnings	(7.01 B)
	Working Capital	2.01 B
	Current Asset	1.11 B
	Current Liabilities	62.1 M
	Net Asset	3.83 B

About Alnylam Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Alnylam Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC